Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

BACKGROUND: Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not been compared prospectively. The primary objective was...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkrief, Arielle, Alessi, Joao M Victor, Ricciuti, Biagio, Brown, Samantha, Rizvi, Hira, Preeshagul, Isabel R, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Egger, Jacklynn V, Chaft, Jamie E, Rudin, Charles M, Riely, Gregory J, Kris, Mark G, Ladanyi, Marc, Chen, Yuan, Hellmann, Matthew D, Shen, Ronglai, Awad, Mark M, Schoenfeld, Adam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373730/
https://www.ncbi.nlm.nih.gov/pubmed/37487667
http://dx.doi.org/10.1136/jitc-2023-006994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373730/
https://www.ncbi.nlm.nih.gov/pubmed/37487667
http://dx.doi.org/10.1136/jitc-2023-006994

Ejemplares similares